Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activityopen access
- Authors
- Choi, Chan-Bum; Liang, Matthew H.; Bae, Sang-Cheol
- Issue Date
- Jan-2016
- Publisher
- BMC
- Citation
- ARTHRITIS RESEARCH & THERAPY, v.18, pp.1 - 5
- Indexed
- SCIE
SCOPUS
- Journal Title
- ARTHRITIS RESEARCH & THERAPY
- Volume
- 18
- Start Page
- 1
- End Page
- 5
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5165
- DOI
- 10.1186/s13075-015-0906-9
- ISSN
- 1478-6354
- Abstract
- Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the agents tested during this period have provided valuable practical insights. There has been incremental progress in defining the minimal clinically important difference (MCID) of key disease manifestations and the view is largely that of the health care providers and not that of the person suffering the disease. This basic methodological work on the MCID should improve the efficiency and the clinical relevance of future trials and their design.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5165)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.